Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Higher plasma drug levels in elderly people living with HIV treated with darunavir.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
      Alkynes/*blood ; Anti-HIV Agents/*blood ; Atazanavir Sulfate/*blood ; Benzoxazines/*blood ; Cyclopropanes/*blood ; Darunavir/*blood ; HIV Infections/*drug therapy; Adult ; Aged ; Alkynes/adverse effects ; Anti-HIV Agents/adverse effects ; Atazanavir Sulfate/adverse effects ; Benzoxazines/adverse effects ; Case-Control Studies ; Cross-Sectional Studies ; Cyclopropanes/adverse effects ; Darunavir/adverse effects ; Drug Interactions ; HIV Infections/blood ; Humans ; Male ; Middle Aged ; Plasma/chemistry ; Sweden
    • نبذة مختصرة :
      Background: The proportion of elderly people living with HIV-1 (PLHIV) is rising. In older patients, comorbidities and concomitant medications are more frequent, increasing the risk of potential drug-drug interactions (PDDIs). Data on the pharmacokinetics of ART in individuals aged ≥ 65 years of age are scarce. We compared plasma drug levels of ART, PDDIs, and side-effects in PLHIV aged ≥ 65 years of age, with controls ≤ 49 years of age.
      Methods: Patients ≥ 65 years of age and controls ≤ 49 years of age, all of whom were on stable treatment with atazanavir (ATV), darunavir (DRV), or efavirenz (EFV) were included cross-sectionally. Plasma drug levels of ART were analyzed, comorbidities, concomitant medication, adherence, and side-effects recorded, and PDDIs analyzed using drug interactions databases.
      Results: Between 2013 and 2015, we included 100 individuals ≥ 65 years of age (study group) and 99 controls (≤ 49 years of age). Steady-state DRV concentrations were significantly higher in the study group than in the control group (p = 0.047). In the ATV group there was a trend towards a significant difference (p = 0.056). No significant differences were found in the EFV arm. The DRV arm had a higher frequency of reported side-effects than the ATV and EFV arms in the study group (36.7% vs. 0% and 23.8% respectively (p = 0.014), with significant differences between DRV vs. ATV, and EFV vs. ATV).
      Conclusions: Higher steady-state plasma levels of DRV and ATV (but not EFV) were found in PLHIV aged ≥ 65 years of age, compared to controls ≤ 49 years of age.
      Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: ET has received honoraria as a speaker from Janssen. CJT and ÅM has received honoraria as speaker and/or scientific advisor from Gilead Sciences, and GlaxoSmithKline/ViiV. AT reports during the conduct of the study; personal fees from Gilead, personal fees from Janssen and personal fees from GSK /ViiV outside the submitted work. MG has received research grants from Gilead Sciences and Janssen-Cilag and honoraria as speaker and/or scientific advisor from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen-Cilag, and MSD. LMA has received an unrestricted research grant from Bristol Myers Squibb. For the remaining authors none were declared. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
    • Comments:
      Erratum in: PLoS One. 2021 May 13;16(5):e0251856. (PMID: 33984025)
    • References:
      Health Psychol. 2007 Jan;26(1):40-9. (PMID: 17209696)
      PLoS One. 2011 Feb 23;6(2):e16800. (PMID: 21373194)
      Pharmacol Rev. 2004 Jun;56(2):163-84. (PMID: 15169926)
      J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):193-201. (PMID: 29767640)
      HIV Med. 2017 Aug;18(7):474-481. (PMID: 28116848)
      AIDS Res Hum Retroviruses. 2013 Dec;29(12):1541-6. (PMID: 24088045)
      Br J Clin Pharmacol. 2009 Nov;68(5):690-9. (PMID: 19916993)
      Lancet HIV. 2015 Jul;2(7):e288-98. (PMID: 26423253)
      AIDS. 2008 Jan 2;22(1):89-95. (PMID: 18090396)
      Ann Pharmacother. 2013 Nov;47(11):1429-39. (PMID: 24285760)
      HIV Med. 2013 Aug;14(7):401-9. (PMID: 23433482)
      Ann Intern Med. 2016 Nov 15;165(10):749-750. (PMID: 27842400)
      J Antimicrob Chemother. 2011 Sep;66(9):2107-11. (PMID: 21680580)
      J Antimicrob Chemother. 2013 Jun;68(6):1354-9. (PMID: 23435690)
      Br J Clin Pharmacol. 2020 Jul 21;:. (PMID: 32696528)
      PLoS One. 2019 Oct 9;14(10):e0223224. (PMID: 31596867)
      AIDS Care. 2000 Jun;12(3):255-66. (PMID: 10928201)
      Clin Infect Dis. 2020 Jul 11;71(2):353-362. (PMID: 31428770)
      AIDS Res Hum Retroviruses. 2010 Jun;26(6):635-43. (PMID: 20560793)
      Infect Dis (Lond). 2020 May;52(5):295-329. (PMID: 31928282)
      AIDS. 2004 Jan 1;18 Suppl 1:S19-25. (PMID: 15075494)
      Antivir Ther. 2010;15(3):413-23. (PMID: 20516560)
      AIDS Patient Care STDS. 2019 Mar;33(3):93-103. (PMID: 30844304)
      J Clin Pharmacol. 2008 Oct;48(10):1212-25. (PMID: 18812611)
      BMC Med. 2013 Nov 27;11:251. (PMID: 24283830)
    • الرقم المعرف:
      0 (Alkynes)
      0 (Anti-HIV Agents)
      0 (Benzoxazines)
      0 (Cyclopropanes)
      4MT4VIE29P (Atazanavir Sulfate)
      JE6H2O27P8 (efavirenz)
      YO603Y8113 (Darunavir)
    • الموضوع:
      Date Created: 20210204 Date Completed: 20210723 Latest Revision: 20210723
    • الموضوع:
      20231215
    • الرقم المعرف:
      PMC7861408
    • الرقم المعرف:
      10.1371/journal.pone.0246171
    • الرقم المعرف:
      33539440